The novel antiepileptic drug (AED) perampanel is used in monotherapy and as an adjunctive treatment for focal, focal to bilateral, and generalized tonic-clonic seizures in patients with epilepsy. Perampanel has a high protein-binding ratio (> 95 %) and long half-life (∼105 h) and is mainly metabolized by cytochrome P450 (CYP) 3A4 [1]. Thus, it is highly susceptible to interactions with CYP-inducing AEDs (inducers), such as phenytoin (PHT), carbamazepine (CBZ), and phenobarbital (PB). In contrast, stiripentol is a strong inhibitor of CYP3A4, ...
Seguir leyendo →NOV